SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The company witnessed a 7.44% growth in the revenue at Rs. 688.04 millions for the quarter ended March 2023 as compared to Rs. 640.40 millions during the year-ago period.The Net Loss for the quarter ended March 2023 is Rs. -73.55 millions as compared to Net Profit of Rs. 105.06 millions of corresponding quarter ended March 2022Operating Profit reported a sharp decline to 129.79 millions from 178.29 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 688.04 640.40 7.44 2509.95 4561.32 -44.97 2509.95 4561.32 -44.97
Other Income 14.60 16.02 -8.86 29.41 35.12 -16.26 29.41 35.12 -16.26
PBIDT 129.79 178.29 -27.20 632.29 1752.37 -63.92 632.29 1752.37 -63.92
Interest 16.68 10.26 62.57 60.20 29.17 106.38 60.20 29.17 106.38
PBDT -52.18 168.03 -131.05 406.80 1723.20 -76.39 406.80 1723.20 -76.39
Depreciation 44.16 27.48 60.70 149.19 106.44 40.16 149.19 106.44 40.16
PBT -96.34 140.55 -168.55 257.61 1616.76 -84.07 257.61 1616.76 -84.07
TAX -22.79 35.49 -164.22 62.92 416.28 -84.89 62.92 416.28 -84.89
Deferred Tax 1.67 0.49 240.82 1.37 2.75 -50.18 1.37 2.75 -50.18
PAT -73.55 105.06 -170.01 194.69 1200.48 -83.78 194.69 1200.48 -83.78
Equity 103.76 103.76 0.00 103.76 103.76 0.00 103.76 103.76 0.00
PBIDTM(%) 18.86 27.84 -32.24 25.19 38.42 -34.43 25.19 38.42 -34.43

Kwality Pharma Share Price

1583.75 -80.55 (-4.84%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×